BioCardia (BCDA) vs Radiopharm Theranostics (RADX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
BioCardia (BCDA) has outperformed Radiopharm Theranostics (RADX) over the past year, losing 25.4% versus a loss of 85.3%. Radiopharm Theranostics is the larger company by market cap ($16.2 million vs $16.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCDA | RADX |
|---|---|---|
| Share price | $1.06 | $1.11 |
| Market cap | $16.05M | $16.20M |
| 1-day change | -2.75% | -3.48% |
| YTD return | -15.20% | -78.74% |
| 1-year return | -25.35% | -85.27% |
| 5-year return | -97.59% | — |
| EPS (TTM) | $-0.64 | $-3.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.80 | $16.25 |
| 52-week low | $0.75 | $1.00 |
| Distance from 52-week high | -41.11% | -93.17% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +1362.26% | +1430.63% |
| Average volume | 282.05K | 84.72K |
| Shares outstanding | 15.14M | 14.59M |
| Employees | 17 | 14 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BCDA has outperformed RADX by 59.9 percentage points over the past year.
About BioCardia
BCDA stock →BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
Healthcare · Biotechnology · 17 employees
About Radiopharm Theranostics
RADX stock →Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic.
Healthcare · Biotechnology · 14 employees
BCDA vs RADX FAQ
Which is bigger, BioCardia or Radiopharm Theranostics?
Radiopharm Theranostics (RADX) is larger, with a market capitalization of $16.20M compared with $16.05M for BioCardia (BCDA).
Which stock has performed better over the past year, BCDA or RADX?
BCDA returned -25.35% over the past 12 months, compared with -85.27% for RADX (price return, excluding dividends). Past performance does not predict future results.
Are BioCardia and Radiopharm Theranostics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.